Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Rimini, M; Rimassa, L; Ueshima, K; Burgio, V; Shigeo, S; Tada, T; Suda, G; Yoo, C; Cheon, J; Pinato, D J; Lonardi, S; Scartozzi, M; Iavarone, M; Di Costanzo, G G; Marra, F; Soldà, C; Tamburini, E; Piscaglia, F; Masi, G; Cabibbo, G; Foschi, F G; Silletta, M; Pressiani, T; Nishida, N; Iwamoto, H; Sakamoto, N; Ryoo, B-Y; Chon, H J; Claudia, F; Niizeki, T; Sho, T; Kang, B; D'Alessio, A; Kumada, T; Hiraoka, A; Hirooka, M; Kariyama, K; Tani, J; Atsukawa, M; Takaguchi, K; Itobayashi, E; Fukunishi, S; Tsuji, K; Ishikawa, T; Tajiri, K; Ochi, H; Yasuda, S; Toyoda, H; Ogawa, C; Nishimur, T; Hatanaka, T; Kakizaki, S; Shimada, N; Kawata, K; Tanaka, T; Ohama, H; Nouso, K; Morishita, A; Tsutsui, A; Nagano, T; Itokawa, N; Okubo, T; Arai, T; Imai, M; Naganuma, A; Koizumi, Y; Nakamura, S; Joko, K; Iijima, H; Hiasa, Y; Pedica, F; De Cobelli, F; Ratti, F; Alrighetti, L; Kudo, M; Cascinu, S; Casadei-Gardini, A

doi:10.1016/j.esmoop.2022.100591

A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy.

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis / Rimini, M., Rimassa, L., Ueshima, K., Burgio, V., Shigeo, S., Tada, T., Suda, G., Yoo, C., Cheon, J., Pinato, D.J., Lonardi, S., Scartozzi, M., Iavarone, M., Di Costanzo, G.G., Marra, F., Soldà, C., Tamburini, E., Piscaglia, F., Masi, G., Cabibbo, G., et al.. - In: ESMO OPEN. - ISSN 2059-7029. - 7:6(2022), p. 100591. [10.1016/j.esmoop.2022.100591]